Tacrolimus 0.03% ointment in labial discoid lupus erythematosus: A randomized, controlled clinical trial
Tacrolimus 0.03% ointment in labial discoid lupus erythematosus: A randomized, controlled clinical trial
复制标题
DOI：
10.1002/jcph.537
复制
发表时间：
2015-11-01
影响因子：
2.9
通讯作者：
Zhou, Hongmei
中科院分区：
文献类型：
--
作者：
Wang, Xiangjian;Zhang, Lin;Zhou, Hongmei
In this randomized, controlled clinical trial to compare efficacy and safety, 41 patients with labial discoid lupus erythematosus (DLE) were randomized to 2 groups, either receiving tacrolimus 0.03% ointment (n=22) or triamcinolone acetonide 0.1% cream (n=19). Each patient was treated with 3, 2, and 1 daily doses in the first, second, and third weeks, respectively, for 1 course. After the 3 week treatment, patients with complete disappearance of erosion were followed up for 3 months. After the 3 week application, 20 participants in the tacrolimus group and 19 in the triamcinolone acetonide group completed the study. The rates of complete response were 70% and 89.5% in tacrolimus-treated and triamcinolone acetonide-treated patients, respectively, with no significant difference (P=.235). Reduction in erosion and erythema showed no significant difference between groups (P>.05). Final reduction in reticulation areas and numeric rating scale scores were significantly greater in the tacrolimus group than in the triamcinolone acetonide group (P=.013; P=.048, respectively). Only 1 patient receiving tacrolimus presented with slight discomfort. There was no significant difference in 3 month recurrence rate between the groups (P>.05). Topical tacrolimus is considered as effective as triamcinolone acetonide for the management of labial DLE.
